| Autor: |
Santoso, Adi, Rubiyana, Yana, Wisnuwardhani, Popi Hadi, Kusumawati, Arizah, Septisetyani, Endah Puji, Herawati, Neng, Nurainy, Neni, Harmoko, Rikno, Nuryana, Isa, Izzati, Fauzia Nurul, Sarwono, Ki Ageng, Khaerunnisa, Isyana, Rahmawati, Siti Irma, Bayu, Asep |
| Předmět: |
|
| Zdroj: |
AIP Conference Proceedings; 12/23/2022, Vol. 2606 Issue 1, p1-5, 5p |
| Abstrakt: |
The development of cell lines for the production of therapeutic protein drugs is complex, laborious, and expensive. However, due to the ever-increasing demand, the biomanufacturing process of recombinant proteins has to be steadily improved. Approaches that might be done to increase the production of biologics include continuous optimization, improvement of production, and better cell line development technology. Human erythropoietin (hEPO) is a hormone-like glycoprotein and has a molecular weight of 30,400 Daltons with 3 N-link glycosylation sites. hEPO is very essential and is a major factor in the formation of red blood cells. Decreased levels of hEPO in the body can cause anemia. This makes recombinant hEPO one of the most needed biologics in the world. With that in mind, this study aims to develop cell line capable of producing rhEPO with 2 additional N-links using CHO-DG44 cells. The cells were cultured in an orbital shaker at the speed of 130 rpm at 37oC and 5% CO2 condition and samples were taken on day 6. The results showed three clones, 193, 145, 223 with titer each of 2050+1.92, 1570+1.60 and 1320+1.90 milligrams/liter medium, respectively, with molecular weight of 40 - 50 kDa. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
